Search for: "Pharms v. U.s.*"
Results 41 - 60
of 383
Sorted by Relevance
|
Sort by Date
14 Apr 2018, 11:46 am
See Vanda Pharm. [read post]
4 May 2008, 9:58 pm
FDA, concerning 180-day exclusivity on Risperdal, in which Apotex filed a motion to intervene; Nu-Pharm v. [read post]
22 May 2014, 10:51 am
Merrell Dow Pharm., Inc., 509 U.S. 579, 597 (1993). [read post]
19 Aug 2022, 6:59 am
by Dennis Crouch Par Pharm., Inc. v. [read post]
31 Mar 2020, 9:58 am
Teva Pharm. [read post]
17 Jul 2017, 9:41 am
Par Pharm., Inc. v. [read post]
3 Dec 2021, 2:39 pm
Nuvo Pharm. [read post]
19 Jan 2023, 6:01 pm
by Dennis Crouch Novartis Pharms v. [read post]
Federal Circuit to consider whether a separate written description requirement exists in section 112
23 Aug 2009, 11:18 am
To read the order in Ariad Pharms., Inc. v. [read post]
10 Oct 2007, 8:29 pm
In Abbott Laboratories v. [read post]
17 Dec 2018, 9:39 am
Jazz Pharms., Inc. v. [read post]
5 Mar 2014, 8:57 pm
Sunovion Pharm., Inc., No. 2012-1428 (Fed. [read post]
5 Feb 2017, 1:59 pm
Pharms., Inc., 509 U.S. 579 (1993). [read post]
5 Feb 2017, 1:59 pm
Pharms., Inc., 509 U.S. 579 (1993). [read post]
20 Jun 2019, 8:00 am
In Phio Pharms. [read post]
19 Apr 2016, 12:03 pm
Cir. 2015) (citing Teva Pharm. [read post]
5 Feb 2018, 11:16 am
;accord Caraco Pharm. [read post]
26 May 2011, 7:09 am
Amphastar Pharm., Inc., 525 F.3d 1334, 1349 (Fed. [read post]
9 Sep 2017, 11:04 am
While “[w]e have recognized that inherency may supply a missing claim limitation in an obviousness analysis,” PAR Pharm., Inc. v. [read post]
30 Oct 2013, 5:42 am
” Ariad Pharms., Inc. v. [read post]
